Ascendis Pharma A/S (ASND) Q2 2015 Earnings Results

Ascendis Pharma Misses on EPS, Stock Down 1.43%

Ascendis Pharma reported a larger-than-expected loss per share, which contributed to a decline in its stock price by 1.43%. The lack of revenue figures and guidance may raise concerns among investors about the company's current performance and future outlook. Overall, the results indicate challenges ahead for the company.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.73	N/A	-52.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on the numerical results.

Ascendis Pharma Misses on EPS, Stock Down 1.43%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma Misses on EPS, Stock Down 1.43%

Key numbers

Management commentary